Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting

References

• BresslerNMBresslerSBCongdonNGPotential public health impact of Age-Related Eye Disease Study results: AREDS report no 11Arch Ophthalmol2003121111621162414609922
   PubMed Web of Science ®Google Scholar
• KleinRPetoTBirdAVannewkirkMRThe epidemiology of age-related macular degenerationAm J Ophthalmol32004137348649515013873
   PubMed Web of Science ®Google Scholar
• CongdonNO’ColmainBKlaverCCCauses and prevalence of visual impairment among adults in the United StatesArch Ophthalmol2004122447748515078664
   PubMed Web of Science ®Google Scholar
• FriedmanDSO’ColmainBJMunozBPrevalence of age-related macular degeneration in the United StatesArch Ophthalmol2004122456457215078675
   PubMed Web of Science ®Google Scholar
• VingerlingJRDielemansIHofmanAThe prevalence of age-related maculopathy in the Rotterdam StudyOphthalmology199510222052107862408
   PubMed Web of Science ®Google Scholar
• KahnHALeibowitzHMGanleyJPThe Framingham Eye Study. I. Outline and major prevalence findingsAm J Epidemiol197710611732879158
   PubMed Web of Science ®Google Scholar
• ForanSWangJJMitchellPCauses of visual impairment in two older population cross-sections: the Blue Mountains Eye StudyOphthalmic Epidemiol200310421522514628964
   PubMed Web of Science ®Google Scholar
• SpaideRFLaudKFineHFIntravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degenerationRetina200626438339016603955
   PubMed Web of Science ®Google Scholar
• RosenfeldPJMoshfeghiAAPuliafitoCAOptical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degenerationOphthalmic Surg Lasers Imaging200536433133516156152
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med52006355141419143117021318
   PubMed Web of Science ®Google Scholar
• BashshurZFHaddadZASchakalAJaafarRFSaabMNoureddinBNIntravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective studyAm J Ophthalmol2008145224925618067876
   PubMed Web of Science ®Google Scholar
• BrownDMMichelsMKaiserPKHeierJSSyJPIanchulevTRanibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR studyOphthalmology200911615765e5519118696
   PubMed Web of Science ®Google Scholar
• MartinDFMaguireMGYingGSGrunwaldJEFineSLJaffeGJRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
   PubMed Web of Science ®Google Scholar
• FerraraNDamicoLShamsNLowmanHKimRDevelopment of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degenerationRetina200626885987017031284
   PubMed Web of Science ®Google Scholar
• MordentiJCuthbertsonRAFerraraNComparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administrationToxicol Pathol199927553654410528633
   PubMed Web of Science ®Google Scholar
• BrownDMKaiserPKMichelsMRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
   PubMed Web of Science ®Google Scholar
• KaiserPKBlodiBAShapiroHAcharyaNRAngiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degenerationOphthalmology2007114101868187517628683
   PubMed Web of Science ®Google Scholar
• MitchellPKorobelnikJFLanzettaPRanibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trialsBr J Ophthalmol201094121319443462
   PubMed Web of Science ®Google Scholar
• HeierJSAntoszykANPavanPRRanibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose studyOphthalmology20061134633. e1e416483659
   PubMed Web of Science ®Google Scholar
• RegilloCDBrownDMAbrahamPRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1Am J Ophthalmol2008145223924818222192
   PubMed Web of Science ®Google Scholar
• BoyerDSHeierJSBrownDMFrancomSFIanchulevTRubioRGA Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degenerationOphthalmology200911691731173919643495
   PubMed Web of Science ®Google Scholar
• HolzFGKorobelnikJFLanzettaPThe effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease modelInvest Ophthalmol Vis Sci201051140541219661237
   PubMed Web of Science ®Google Scholar
• BrownDMRegilloCDAnti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patientsAm J Ophthalmol2007144462763717893015
   PubMed Web of Science ®Google Scholar
• AtmaniKVoigtMLe TienVRanibizumab for retinal angiomatous proliferation in age-related macular degenerationEye (Lond)20102471193119820150927
   PubMed Web of Science ®Google Scholar
• MendrinosEMangiorisGPapadopoulouDDonatiGPournarasCOne year results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degenerationInvest Ophthalmol Vis Sci2009
   Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• FerraraNKerbelRSAngiogenesis as a therapeutic targetNature2005438707096797416355214
   PubMed Web of Science ®Google Scholar
• SacuSMichelsSPragerFRandomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term resultsEye200923122223222719169239
   PubMed Web of Science ®Google Scholar
• RichRMRosenfeldPJPuliafitoCAShort-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degenerationRetina200626549551116770255
   PubMed Web of Science ®Google Scholar
• ConradPWZacksDNJohnsonMWIntravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degenerationClin Ophthalmol20082472773319668423
   PubMedGoogle Scholar
• LeydoltCMichelsSPragerFEffect of intravitreal bevacizumab (Avastin(R)) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month resultsActa Ophthalmol201088559460019485959
   PubMed Web of Science ®Google Scholar
• SubramanianMLNessSAbediGBevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trialAm J Ophthalmol20091486875882e119800611
   PubMed Web of Science ®Google Scholar
• StepienKERosenfeldPJPuliafitoCAComparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degenerationRetina20092981067107319696701
   PubMed Web of Science ®Google Scholar
• LandaGAmdeWDoshiVComparative study of intravitreal bevacizumab (avastin) versus ranibizumab (lucentis) in the treatment of neovascular age-related macular degenerationOphthalmologica2009223637037519590252
   PubMed Web of Science ®Google Scholar
• GamulescuMARadeckVLustingerBFinkBHelbigHBevacizumab versus ranibizumab in the treatment of exudative age-related macular degenerationInt Ophthalmol201030326126619633973
   PubMedGoogle Scholar
• TufailAPatelPJEganCBevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked studyBMJ2010340c245920538634
   PubMed Web of Science ®Google Scholar
• BashshurZFSchakalAHamamRNEl HaibiCPJaafarRFNoureddinBNIntravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degenerationArch Ophthalmol2007125101357136117923543
   PubMedGoogle Scholar
• GhaziNGKnapeRMKirkTQTiedemanJSConwayBPIntravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferationRetina200828568969518463511
   PubMed Web of Science ®Google Scholar
• GoffMJJohnsonRNMcDonaldHRAiEJumperJMFuAIntravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degenerationRetina200727443243817420694
   PubMed Web of Science ®Google Scholar
• GlynnRJRosnerBAccounting for the correlation between fellow eyes in regression analysisArch Ophthalmol199211033813871543458
   PubMed Web of Science ®Google Scholar
• KatzJZegerSLiangKYAppropriate statistical methods to account for similarities in binary outcomes between fellow eyesInvest Ophthalmol Vis Sci1994355246124658163336
   PubMed Web of Science ®Google Scholar
• MurdochIEMorrisSSCousensSNPeople and eyes: statistical approaches in ophthalmologyBr J Ophthalmol19988289719739828786
   PubMed Web of Science ®Google Scholar
• HolzFGKorobelnikJFLanzettaPThe effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease modelInvest Ophthalmol Vis Sci201051140541219661237
   PubMed Web of Science ®Google Scholar
• FungAELalwaniGARosenfeldPJAn optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degenerationAm J Ophthalmol2007143456658317386270
   PubMed Web of Science ®Google Scholar
• LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO StudyAm J Ophthalmol2009148143. e158. e119376495
   PubMed Web of Science ®Google Scholar